Cardiovascular morbidity and endothelial dysfunction in chronic haemodialysis patients: Is homocyst(e)ine the missing link?

Nephrology Dialysis Transplantation

Volumn 14, Issue 8, 1999, Pages 1934-1942

  Kunz, Kristian ^a   Petitjean, Philippe ^a   Lisri, Mohamed ^a   Chantrel, Frances ^a   Koehl, Christian ^b   Wiesel, Marie Louise ^c   Cazenave, Jean Pierre ^c   Moulin, Bruno ^a   Hannedouche, Thierry P ^a  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c Etablissement de Transfus Sanguine   (France)

Author keywords

Chronic renal failure; Endothelium; Haemodialysis; Haemostatic factors; Homocyst(e)ine

Indexed keywords

ENDOTHELIN 1; FIBRINOGEN; FOLIC ACID; HOMOCYSTEINE; PLASMINOGEN ACTIVATOR INHIBITOR 1; VON WILLEBRAND FACTOR;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIET SUPPLEMENTATION; FEMALE; HEMODIALYSIS; HEMOSTASIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MALNUTRITION; MORBIDITY; MORTALITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RISK FACTOR; VASCULAR DISEASE; VASCULAR ENDOTHELIUM;

AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; COHORT STUDIES; ENDOTHELIUM, VASCULAR; FEMALE; FOLIC ACID; HEMATINICS; HEMOSTASIS; HOMOCYSTEINE; HOMOCYSTINE; HUMANS; MALE; MIDDLE AGED; MORBIDITY; NUTRITIONAL STATUS; RENAL DIALYSIS; RISK FACTORS; TIME FACTORS;

EID: 0032793447     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/14.8.1934     Document Type: Article

References (47)

1. Raine AEG. Ischaemic heart disease in patients with renal failure. Issues Nephrosci 1992; 3: 75-83
2. Vincenti F, Amend WJ, Abele J, Feduska NJ, Salvatierra O. The role of hypertension in hemodialysis-associated atherosclerosis. Am J Med 1980; 68: 363-369
3. Ibels LS, Alfrey AS, Huffer WE et al. Arterial calcifications and pathology in uremic patients undergoing dialysis. Am J Med 1979; 66: 790-796
4. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-809
5. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long term incidence of ischaemic heart disease in the Norwick Park Heart Study. Lancet 1993; 342: 1076-1079
6. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo J. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 332: 635-641
7. Mudd SH, Levy HL, Skovby F. Disorders of transsulfuration. In: Scriver CR, Beaudet AL, Sly WS, Valle D, (eds. The Metabolic and Molecular Bases of Inherited Disease. McGraw-Hill, Inc., New York 1995; 1279-1327
8. Selhub J, Jacques PF, Bostom AG et al. Association between plasma homocysteine concentrations and extracranial carotidartery stenosis [see comments]. N Engl J Med 1995; 332: 286-291
9. Stampfer MJ, Malinow MR, Willett WC et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. J Am Med Assoc 1992; 268: 877-881
10. Stampfer MJ, Malinow MR. Can lowering homocysteine levels reduce cardiovascular risk? [editorial; comment]. N Engl J Med 1995; 332: 328-329
11. Chauveau P, Chadefaux B, Coude M et al. Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int 1993; 41 [Suppl]: S72-S77
12. Wilcken DEL, Dudman NPB, Tyrell PA, Robertson MR. Folic acid lowers elevated plasma homocysteine in chronic renal insufficiency: possible implications for prevention of vascular disease. Metabolism 1988; 37: 697-701
13. The Criteria Committee of the New York Heart Association. Nomenclature and Criteria fort Diagnosis of Diseases of the Heart and Great Vessels. Little, Brown and Company, Boston: 1994
14. Hyman JB, Epstein FH. A study of the correlation between roentgenographic and post-mortem calcifications of the aorta. Am Heart J 1954; 47: 540-543
15. Araki A, Sako Y, Fukushima Y et al. Plasma sulfhydryl-containing amino acids in patients with cerebral infarction and in hypertensive subjects. Atherosclerosis 1989; 79: 139-146
16. Wiesel M-L, Mossard J-M, Grunebaum L, Cazenave J-P, Sacrez A. Variations du facteur Willebrand et du fibrinogène plasmatique en pathologie coronaire. Ann Biol Clin 1992; 50: 15-19
17. 15N) nitrate in biological fluids. Anal Biochem 1982; 126: 131-138
18. Wallenstein S, Zucker CL, Fleiss JL. Some statistical methods useful in circulation research. Circ Res 1980; 47: 1-9
19. Bostom AG, Shemin D, Lapane KL et al. Hyperhomocysteinaemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: a case-control study. Atherosclerosis 1995; 114: 93-103
20. Hultberg B, Andersson A, Sterner G. Plasma homocysteine in renal failure. Clin Nephrol 1993; 40: 230-235
21. Ueland PM, Refsum H, Stabler SP et al. Total homocysteine in plasma or serum: methods and clinical applications. Clin Chem 1993; 39: 1764-1779
22. Perna AF, Ingrosso D, De-Santo NG, Galletti P, Zappia V. Mechanism of erythrocyte accumulation of methylation inhibitor S-adenosylhomocysteine in uremia. Kidney Int 1995; 47: 247-253
23. Pathasarathy S. Oxidation of low-density lipoprotein by thiol compounds leads to its recognition by the acetyl LDL receptor. Biochim Biophys Acta 1987; 917: 337-340
24. Harpel PC, Chang VT, Borth W. Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: a potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism. Proc Natl Acad Sci USA 1992; 89: 10193-10197
25. Charney DI, Walton DF, Cheung AK. Atherosclerosis in chronic renal failure. Curr Opin Nephrol Hypertension 1993; 2: 876-882
26. Cressman MD, Heyka RJ, Paganini EP et al. Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 1992; 86: 475-482
27. Witteman JCM, Kok FJ, van Saase JLCM, Valkenburg HA. Aortic calcifications as a predictor of cardiovascular mortality. Lancet 1986; ii: 1120-1122
28. Fitzpatrick LA, Severson WD, Ingram RT. Diffuse calcifications in the human coronary arteries. Association of osteopontin with atherosclerosis. J Clin Invest 1994; 94: 1597-1604
29. Dudman NP, Hicks C, Wang J, Wilcken DE. Human arterial endothelial cell detachment in vitro: its promotion by homocysteine and cysteine. Atherosclerosis 1991; 91: 77-83
30. Hajjar KA. Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor. J Clin Invest 1993; 91: 2873-2879
31. Lentz SR, Sadler JE. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest 1991; 88: 1906-1914
32. Lentz SR, Sadler JE. Homocysteine inhibits von Willebrand factor processing and secretion by preventing transport from the endoplasmic reticulum. Blood 1993; 81: 683-689
33. Rodgers GM, Conn MT. Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. Blood 1990; 75: 895-901
34. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 1993; 118: 956-963
35. Haaber AB, Eidemak I, Jensen T, Feldt-Rasmussen B, Strandgaard S. Vascular endothelial cell function and cardiovascular risk factors in patients with chronic renal failure. J Am Soc Nephrol 1995; 5: 1581-1584
36. Von-Eckardstein A, Malinow MR, Upson B et al. Effects of age, lipoproteins, and hemostatic parameters on the role of homocyst(e)inemia as a cardiovascular risk factor in men. Arterioscler Thromb 1994; 14: 460-464
37. Gris JC, Branger B, Vecina F et al. Increased cardiovascular risk factors and features of endothelial activation and dysfunction in dialyzed uremic patients. Kidney Int 1994; 46: 807-813
38. Warrell RP, Hultin MB, Coller BS. Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in renal failure. Am J Med 1979; 66: 226-228
39. Lowe GDO. Laboratory investigation of pre-thrombolic states. In: Poller L, Thomson JM, eds. Thrombosis and its Management. Churchill Livingstone, Edinburgh: 1993; 31-46
40. Juhan-Vague I, Alessi MC. Plasminogen activator inhibitor 1 and atherothrombosis. Thromb Haemostasis 1993; 70: 138-143
41. Hamsten A, Faire U, Walldius G et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; i: 3-9
42. Cortellaro M, Cofrancesco E, Boschetti C et al. Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients: a case-control study. Atheroscler Thromb 1993; 13: 1412-1417
43. Sawdey MS, Loskutoff DJ. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta. J Clin Invest 1991; 88: 1346-1353
44. Erickson P, Kallin B, van't Hooft FM, Bavenholm P, Hamsten A. Allele specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 1995; 92: 1851-1855
45. Bostom AG, Shemin D, Lapane KL et al. High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int 1996; 49: 147-152
46. van Guldener C, Janssen MJ, Lambert J et al. No change in impaired endothelial function after long-term folic acid therapy of hyperhomocysteinaemia in haemodialysis patients. Nephrol Dial Transplant 1998; 13: 106-112
47. Hong SY, Yang DH, Chang SK. Plasma homocysteine, vitamin B6, vitamin B12 and folic acid in end-stage renal disease during low-dose supplementation with folic acid. Am J Nephrol 1998; 18: 367-372